Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation

Apremilast (APR) is a selective phosphodiesterase 4 inhibitor administered orally in the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The low solubility and permeability of this drug hinder its dermal administration. The purpose of this study was to design and cha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmaceuticals (Basel)
Autors principals: Sarango-Granda, Paulo, Silva-Abreu, Marcelle, Calpena, Ana Cristina, Halbaut, Lyda, Fábrega, María-José, Rodríguez-Lagunas, María J., Díaz-Garrido, Natalia, Badia, Josefa, Espinoza, Lupe Carolina
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7767333/
https://ncbi.nlm.nih.gov/pubmed/33371334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13120484
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars